INSM Insmed Inc
Company Analysis
Latest News
🔴 Insmed falls 4.0% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
Stanley Druckenmiller increases stake in biotech Insmed by 23%
Billionaire investor Stanley Druckenmiller's Duquesne Family Office increased its position in Insmed (INSM) by 23.45% during the second quarter of 2026,...
Insmed's second quarter revenue of $425.5M beats estimates, driven by strong BRINSUPRI sales, leading to raised FY2026 guidance.
Insmed reported second quarter 2026 total revenue of $425.5 million and a net loss of $0.06 per share, significantly beating analyst estimates for both revenue...
Insmed Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Consensus estimates project Q2 2026 revenue of $393.4 million and an EPS loss of $0.69, while the current stock price of $101.49 remains well below the average...
Insmed's first quarter 2026 revenue of $306M crushes estimates, driven by a strong BRINSUPRI launch.
Insmed reported first quarter 2026 revenue of $306.0 million and a net loss of $0.76 per share, significantly beating analyst expectations on both the top and...
Insmed Inc Q1 2026 Earnings Preview: What Analysts Expect on May 07, 2026
For the first quarter of 2026, analysts anticipate Insmed to report consensus revenue of $114.8 million and an EPS loss of -$0.92, with the current stock price...